🇺🇸 FDA
Pipeline program

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

262SP101(ION464-CS1)

Phase 1 other active

Quick answer

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) for Multiple System Atrophy is a Phase 1 program (other) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Multiple System Atrophy
Phase
Phase 1
Modality
other
Status
active

Clinical trials